Sign in
Taking peopleNo phase

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

Key facts

Who runs it
Hellenic Institute for the Study of Sepsis
Where
Greece19 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
650 people, planned
Started
8 Nov 2024
Expected to end
8 Jun 2028
Type of study
Observational, 4 groups
Treatments tested
  • Blood samples and Oropharyngeal swab
  • Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Record updated
6 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Group A (healthy controls)
  • Adults (18 years or more) of both genders (Female/Male: 50/50 ratio)
  • No history of severe pneumonia (sCAP, COVID-19 or HAP)
  • Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group B (CVRD controls)
  • Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  • No history of severe pneumonia (sCAP, COVID-19 or HAP)
  • At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group C (COVID-19 survivors)
  • Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  • Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia
  • SoC treatment for acute COVID-19 with dexamethasone; Group D (sCAP survivors)
  • Adults (18 years or more) of both genders
  • Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit
  • SoC treatment for sCAP with antibiotics

Who cannot take part

  • Any other co-existing disorder generating CVRD symptoms
  • Any other co-existing disorder generating CVRD symptoms
  • Pregnancy or lactation; Group C (COVID-19 survivors)
  • Medical history of severe congestive heart failure (Stage III-IV)
  • Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
  • Medical history of severe congestive heart failure (Stage III-IV)
  • Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP
  • Group A (healthy controls)
  • Presence of two or more comorbidities
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation; Group B (CVRD controls)
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation; Group D (sCAP survivors)
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation

This trial is currently available in Greece.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.

Read full original descriptionShow less

The overall concept underpinning "Homi-lung" is to investigate the time course of host-microbiome interactions during \& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \& after pneumonia.

The 4 groups in the trial

  • Healthy controls

    Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia.

    Treatment: Blood samples and Oropharyngeal swab

  • CVRD controls

    Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia

    Treatment: Blood samples and Oropharyngeal swab and Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

  • COVID-19 survivors

    Patients cured of acute COVID-19

    Treatment: Blood samples and Oropharyngeal swab and Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

  • sCAP survivors

    Patients cured of severe community-acquired pneumonia

    Treatment: Blood samples and Oropharyngeal swab and Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2
Record updated
6 November 2026